MB 1
BULLETS
Free CME
Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Review Question - QID 213371

Level of Evidence Levels of Evidence Level 2 QID: 213371 (M1.OMB.19.4868)
In scope icon N/A A
QID 213371 (Type "213371" in App Search)
A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. Because the novel drug has been determined to have few side effects, this trial will offer the novel drug to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy. Which of the following best describes the level of evidence that this study can offer?
Type in at least one full word to see suggestions list